-
公开(公告)号：US20230322895A1
公开(公告)日：2023-10-12
申请号：US18046408
申请日：2022-10-13
Applicant: Immunocore Limited
Inventor： Conor HAYES , Linda HIBBERT , Nathaniel Ross LIDDY , Tara MAHON , Marine RAMAN
IPC: C07K14/725 , C12N15/62 , A61P35/00 , C07K16/30 , C07K16/28
CPC classification number: C07K14/7051 , A61P35/00 , C07K16/2833 , C07K16/30 , C12N15/62 , C07K2317/56 , C07K2317/64 , C07K2317/92 , C07K2317/94 , C07K2319/035
Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号：US20230192806A1
公开(公告)日：2023-06-22
申请号：US17817301
申请日：2022-08-03
Applicant: IMMUNOCORE LIMITED
Inventor： Tara MAHON , Yi LI
IPC: C07K14/725 , C07K16/28 , A61K47/64 , A61K38/00
CPC classification number: C07K14/7051 , C07K16/2809 , A61K47/6425 , C07K2319/30 , A61K38/00 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
-
Patent Agency Ranking
公开(公告)号：US20210355188A1
公开(公告)日：2021-11-18
申请号：US16624853
申请日：2018-06-19
Applicant: IMMUNOCORE LIMITED
Inventor： Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号：US20190092834A1
公开(公告)日：2019-03-28
申请号：US16092174
申请日：2017-04-07
Applicant: IMMUNOCORE LIMITED
Inventor： Conor HAYES , Linda HIBBERT , Nathaniel Ross LIDDY , Tara MAHON , Marine RAMAN
IPC: C07K14/725 , A61P35/00 , C12N15/62 , C07K16/30 , C07K16/28
Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号：US20230416335A1
公开(公告)日：2023-12-28
申请号：US18324425
申请日：2023-05-26
Applicant: Immunocore Limited
Inventor： Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
CPC classification number: C07K14/7051 , A61K47/6849 , A61P35/00 , A61K35/17 , A61K45/06 , C07K16/2809 , A61K38/00
Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号：US20220177541A1
公开(公告)日：2022-06-09
申请号：US17552300
申请日：2021-12-15
Applicant: IMMUNOCORE LIMITED
Inventor： Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号：US20190106475A1
公开(公告)日：2019-04-11
申请号：US16087041
申请日：2017-03-22
Applicant: IMMUNOCORE LIMITED
Inventor： Tara MAHON , Yi LI
IPC: C07K14/725 , C07K16/28
Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
-
-
-
-
-
-
Search Results
7
records
(took 0.014 seconds)
